|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�� |
|
�����γ�ϸ�� |
|
ϸ������ |
|
�°����� |
| ��������������� | |
|
�˾����� |
|
���������� |
|
������У |
| PubMed | |
|
Article by |
|
Article by |
|
Article by |
���������γ�ϸ�������°����Ƶ��о���չ
�˾�����, ����������, ������У
�ڶ���ҽ��ѧ����ҽԺƤ����
����Ϊ�°����ѹ�Ϊ����,�������û����в���ȷ,�ı�ϸ����ֳ��Ӧ�������鷢���°�ЧӦ�Ļ��ơ������յ������γ�ϸ�������Ķ���ϸ�����ӡ���Ӱ�����ϸ���ֻ�������ְ������Ӱ�켰���ϸ����ֳ��˫�����õȷ��������������
[2] Goering PL,Aposhian HV,Mass MJ,et al.The enigma of arsenic carcinogenesis:role of metabolism.Toxicol Sci,1999,49(1):5-14.
[3] Germolec DR,Yoshida T,Gaido K,et al.Arsenic induces overexpression of growth factors in human keratinocytes.Toxicol Appl Pharmacol,1996,141(1):308-318.
[4] Luster ML,Wilmer JL,Germolec DR,et al.Role of keratinocyte-derived cytokines in chemical toxicity.Toxicol Lett,1995,82-83:471-476.
[5] Germolec DR ,Spalding J,Yu HS,et al.Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors.Am J Pathol,1998,153(6):1775-1785.
[6] Corsini E,Asti L,Viviani B,et al.Sodium arsenate induces overproduction of interleukin-1 alpha in murine keratinocytes:role of mitochondria.JInvest Dermatol,1999,113(5):760-765.
[7] Kachinskas DJ,Phillips MA,Qin Q,et al.Arsenate perturbation of human keratinocyte differentiaton.Cell Growth Differ,1994,5(11):1235-1241.
[8] Kachinskas DJ,Qin Q,Phillips MA,et al .Arsenate supression of human keratinocyte programming.Mutat Res,1997,386(3):253-261.
[9] Avernathy CO,Liu YP,Longfellow D,et al .Arsenic;health effects,mechanisms of actions,and research issues.Environ Health Perspect,1999,107(7):593-597.
[10] Hsu CH,Yang SA,Wang JY,et al.Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan.Br J Cancer,1999,80(7):1080-1086.
[11] Castren K,Ranki A,Welsh JA,et al.Infrequent p53 mutations in arsenicrelated skin lesions.Oncol Res,1998,10(9):475-482.
[12] Chang CH,Tsai RK,Chen GS,et al.Expression of bcl-2,p53 and Ki-67in arsenical skin cancers.J Cutan Pathol,1998,25(9):457-462.
[13] Hamadeh HK ,Vargas M,Lee E,et al.Arsenic disrupts cellular levels of p53 and mdm2:a potential mechanism of carcinogenesis.Biochem Biophys Res Commun,1999,263(2):446-449.
[14] Mass MJ,Wang L.Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells:a model for a mechanism of carcinogenesis .Mutat Res,1997,386(3):263-277.
[15] Larochette N,Decaudin D,Jacotot E,et al.Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore .Exp Cell Res,1999,249(2):413-421.
[16] Park WH ,Seol JG,Kim ES,et al.Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor,p21,and apoptosis.Cancer Res,2000,60(11):3065-3071.
[17] Akao Y,Yamada H,Nakagawa Y.Arsenic-induced apoptosis in malignant cells in vitro.Leuk Lymphoma,2000,37(1-2):53-63.
[18] Trouba KJ,Wauson EM,Vorce RL.Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling.Toxicol Appl Pharmacol,2000,164(2):161-170.